Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cambrex Co. stock logo
CBM
Cambrex
$59.99
$59.99
$33.80
$60.29
$2.02B2.14218,726 shsN/A
Eidos Therapeutics, Inc. stock logo
EIDX
Eidos Therapeutics
$122.21
$123.21
$28.39
$132.54
$4.75B-0.16128,113 shsN/A
Forty Seven Inc stock logo
FTSV
Forty Seven
$95.51
$95.51
$5.53
$95.51
$4.60B0.41.61 million shsN/A
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
$2.15
-2.3%
$2.06
$1.04
$3.73
$328.00M1.182.18 million shs1.46 million shs
Xencor, Inc. stock logo
XNCR
Xencor
$7.94
-5.7%
$8.71
$7.16
$27.24
$565.09M0.85789,753 shs564,037 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cambrex Co. stock logo
CBM
Cambrex
0.00%0.00%0.00%0.00%0.00%
Eidos Therapeutics, Inc. stock logo
EIDX
Eidos Therapeutics
0.00%0.00%0.00%0.00%0.00%
Forty Seven Inc stock logo
FTSV
Forty Seven
0.00%0.00%0.00%0.00%0.00%
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
0.00%+1.17%+3.10%+10.46%-24.56%
Xencor, Inc. stock logo
XNCR
Xencor
0.00%+3.26%-12.90%+0.42%-53.89%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cambrex Co. stock logo
CBM
Cambrex
N/AN/AN/AN/AN/AN/AN/AN/A
Eidos Therapeutics, Inc. stock logo
EIDX
Eidos Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Forty Seven Inc stock logo
FTSV
Forty Seven
N/AN/AN/AN/AN/AN/AN/AN/A
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
4.0357 of 5 stars
3.50.00.04.23.91.70.6
Xencor, Inc. stock logo
XNCR
Xencor
3.9886 of 5 stars
3.42.00.03.91.90.81.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cambrex Co. stock logo
CBM
Cambrex
0.00
N/AN/AN/A
Eidos Therapeutics, Inc. stock logo
EIDX
Eidos Therapeutics
0.00
N/AN/AN/A
Forty Seven Inc stock logo
FTSV
Forty Seven
0.00
N/AN/AN/A
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
3.00
Buy$5.00132.56% Upside
Xencor, Inc. stock logo
XNCR
Xencor
2.75
Moderate Buy$28.00252.64% Upside

Current Analyst Ratings Breakdown

Latest FTSV, CBM, HRTX, EIDX, and XNCR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/9/2025
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$6.00
5/8/2025
Xencor, Inc. stock logo
XNCR
Xencor
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$22.00 ➝ $6.00
4/30/2025
Xencor, Inc. stock logo
XNCR
Xencor
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$31.00
4/21/2025
Xencor, Inc. stock logo
XNCR
Xencor
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform
4/11/2025
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00 ➝ $4.00
(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cambrex Co. stock logo
CBM
Cambrex
$532.09M3.80$3.91 per share15.36$19.48 per share3.08
Eidos Therapeutics, Inc. stock logo
EIDX
Eidos Therapeutics
$26.69M177.99N/AN/A$4.57 per share26.74
Forty Seven Inc stock logo
FTSV
Forty Seven
$15.68M293.33N/AN/A$7.52 per share12.70
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
$144.29M2.27N/AN/A($0.22) per share-9.77
Xencor, Inc. stock logo
XNCR
Xencor
$110.49M5.11N/AN/A$9.63 per share0.82
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cambrex Co. stock logo
CBM
Cambrex
$92.41M$2.7721.66N/A5.96%5.38%2.50%N/A
Eidos Therapeutics, Inc. stock logo
EIDX
Eidos Therapeutics
-$37.83M-$1.03N/AN/AN/AN/A-65.21%-53.04%N/A
Forty Seven Inc stock logo
FTSV
Forty Seven
-$87.62M-$2.34N/AN/AN/AN/A-50.38%-44.35%N/A
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
-$13.58M-$0.06N/AN/AN/A-5.24%N/A-3.43%8/5/2025 (Estimated)
Xencor, Inc. stock logo
XNCR
Xencor
-$232.62M-$3.06N/AN/AN/A-181.17%-31.94%-22.19%8/4/2025 (Estimated)

Latest FTSV, CBM, HRTX, EIDX, and XNCR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/4/2025Q2 2025
Xencor, Inc. stock logo
XNCR
Xencor
-$0.78N/AN/AN/A$22.59 millionN/A
5/8/2025Q1 2025
Xencor, Inc. stock logo
XNCR
Xencor
-$0.60-$0.66-$0.06-$0.66$23.44 million$32.73 million
5/6/2025Q1 2025
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
-$0.01$0.01+$0.02$0.01$37.08 million$38.90 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cambrex Co. stock logo
CBM
Cambrex
N/AN/AN/AN/AN/A
Eidos Therapeutics, Inc. stock logo
EIDX
Eidos Therapeutics
N/AN/AN/AN/AN/A
Forty Seven Inc stock logo
FTSV
Forty Seven
N/AN/AN/AN/AN/A
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
N/AN/AN/AN/AN/A
Xencor, Inc. stock logo
XNCR
Xencor
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cambrex Co. stock logo
CBM
Cambrex
0.76
2.37
1.70
Eidos Therapeutics, Inc. stock logo
EIDX
Eidos Therapeutics
0.14
11.10
11.10
Forty Seven Inc stock logo
FTSV
Forty Seven
N/A
14.81
14.81
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
N/A
2.40
1.76
Xencor, Inc. stock logo
XNCR
Xencor
0.16
5.89
5.89

Institutional Ownership

CompanyInstitutional Ownership
Cambrex Co. stock logo
CBM
Cambrex
90.96%
Eidos Therapeutics, Inc. stock logo
EIDX
Eidos Therapeutics
31.40%
Forty Seven Inc stock logo
FTSV
Forty Seven
71.77%
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
80.01%
Xencor, Inc. stock logo
XNCR
Xencor
N/A

Insider Ownership

CompanyInsider Ownership
Cambrex Co. stock logo
CBM
Cambrex
1.41%
Eidos Therapeutics, Inc. stock logo
EIDX
Eidos Therapeutics
70.10%
Forty Seven Inc stock logo
FTSV
Forty Seven
37.40%
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
5.86%
Xencor, Inc. stock logo
XNCR
Xencor
5.23%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cambrex Co. stock logo
CBM
Cambrex
1,73233.72 millionN/AOptionable
Eidos Therapeutics, Inc. stock logo
EIDX
Eidos Therapeutics
7038.87 millionN/ANot Optionable
Forty Seven Inc stock logo
FTSV
Forty Seven
5748.16 millionN/ANot Optionable
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
300152.56 million143.62 millionOptionable
Xencor, Inc. stock logo
XNCR
Xencor
28071.17 million67.45 millionOptionable

Recent News About These Companies

Xencor Reports First Quarter 2025 Financial Results
Xencor initiated with an Outperform at William Blair

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cambrex stock logo

Cambrex NYSE:CBM

Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms. The company serves generic drug companies; and companies that discover and commercialize small molecule human therapeutics. The company sells its products directly, as well as through independent agents. Cambrex Corporation was founded in 1981 and is headquartered in East Rutherford, New Jersey.

Eidos Therapeutics stock logo

Eidos Therapeutics NASDAQ:EIDX

Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in phase 3 clinical trial, is an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma, Inc.

Forty Seven stock logo

Forty Seven NASDAQ:FTSV

Forty Seven Inc., a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody. Forty Seven Inc. has a collaboration agreement with Genentech to include third clinical trial in non-Hodgkin's lymphoma. The company was formerly known as CD47 Sciences, Inc. Forty Seven Inc. was incorporated in 2014 and is headquartered in Menlo Park, California.

Heron Therapeutics stock logo

Heron Therapeutics NASDAQ:HRTX

$2.15 -0.05 (-2.27%)
As of 04:00 PM Eastern

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Xencor stock logo

Xencor NASDAQ:XNCR

$7.94 -0.48 (-5.70%)
As of 04:00 PM Eastern

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.